MedTrace Logo

A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands

NCT02875184 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2023-10-10

No results posted yet for this study

Summary

This is a multicenter, prospective, non-interventional, observational single arm study.

100 patients will be recruited in the Netherlands over a one year period. In all cases, the decision to treat the patient with apremilast will be made prior to the decision to enter the subject into this study. Treatment will be according to routine clinical practice and based on recommendations as per the Summary of Product Characteristics (SPC) of apremilast (Otezla®). Each patient will be followed up for a maximum of 24 months.

Conditions

  • Arthritis, Psoriatic

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-06
Primary Completion
2022-06-30
Completion
2022-06-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02875184 on ClinicalTrials.gov